Core Viewpoint - The recent performance fluctuations of multiple products under Lin Yuan's management have drawn significant market attention, with some products underperforming the CSI 300 index and even incurring losses this year [1][2][3] Performance Overview - Lin Yuan has been in the market since 1989, starting with 8,000 yuan, and has built a reputation through long-term value investing, focusing on core holdings like Kweichow Moutai [2] - As of September 26, among the 263 private funds managed by Lin Yuan, 18 funds with disclosed performance have all underperformed the CSI 300 index, with the best-performing fund yielding only 10.05% over the past year compared to the index's 13.25% [2][3] - Several funds, such as "Lin Yuan Investment No. 173" and "Lin Yuan Investment No. 21," have reported losses, with the former down 23.80% since inception and 10.99% over the past year [3] Investment Strategy and Risk Management - Lin Yuan attributes the underperformance to short-term price declines of held assets rather than issues with industry allocation or stock selection, maintaining a long-term holding strategy without additional risk control measures [4] - The investment philosophy emphasizes thorough research on potential holdings over 6-12 months, focusing on companies with long-term viability and profitability [4] - Lin Yuan has a minimal allocation to technology stocks, primarily to meet contractual obligations, and prefers stable traditional industries over volatile sectors [4] Market Outlook - Lin Yuan continues to focus on long-term opportunities in the consumer and pharmaceutical sectors, while avoiding participation in popular sectors like new energy and artificial intelligence due to uncertainty in short-term valuation [5][6] - He predicts that over 70% of investors may underperform the CSI 300 index this year, emphasizing the importance of long-term investment horizons over short-term performance [6] Clarification on Liquidation Risks - Lin Yuan denies rumors of liquidation risks for his products, stating that the only potential for liquidation would be contract expiration, and there are currently no products facing such a situation [6] - He advises investors to verify information through official channels and emphasizes the importance of understanding and accepting the long-term investment strategy before committing [6][7] Industry Perspective - Analysts note that Lin Yuan's strategy reflects the challenges of long-term value investing amid short-term market volatility, particularly in the consumer and pharmaceutical sectors [7] - Investors are advised to consider their risk tolerance and investment horizon when selecting private funds, as the strategy requires patience and acceptance of short-term fluctuations [7]
私募“大佬”林园回应业绩争议：坚持长期持有 否认清盘风险
Nan Fang Du Shi Bao·2025-10-09 16:37